Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long term follow-up

被引：0
|
作者：
Prasad, V.
Baum, R. P.
机构：
[1] Zent Klin Bad Berka GmbH, Dept Nucl Med, Bad Berka, Germany
[2] Zent Klin Bad Berka GmbH, Ctr PET CT, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [1] Impact of Peptide Receptor Radionuclide Therapy Using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on Renal Tubular Function: Long-Term Follow-Up
    Prasad, V
    Baum, R. P.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 132 - 132
  • [2] Impact of two cycles of peptide receptor radionuclide therapy (PRRT) on renal function as determined by repeated Tc-99m DTPA/GFR measurements: comparison between Y-90 DOTA-TATE and Lu-177 DOTA-TATE
    Prasad, V.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S325 - S325
  • [3] Survival benefits and efficacy of peptide receptor radionuclide therapy (PRRT) using Y-90/Lu-177 DOTA-TATE in pancreatic neuroendocrine tumor (pNET)
    Prasad, V.
    Hoersch, D.
    Hommann, M.
    Zachert, C.
    Baum, R. P.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [4] Pancreatic Neuroendocrine Tumor (pNET): Survival Benefits and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Using Y-90/Lu-177 DOTA-TATE
    Prasad, V
    Hoersch, D.
    Hommann, M.
    Zachert, C.
    Baum, R. P.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 132 - 133
  • [5] Lu-177 DOTA-TATE for peptide receptor Radionuclide therapy (PRRT): Organ, tumor, and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S358 - S359
  • [6] Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy
    E. Seregni
    M. Maccauro
    C. Chiesa
    L. Mariani
    C. Pascali
    V. Mazzaferro
    F. De Braud
    R. Buzzoni
    M. Milione
    A. Lorenzoni
    A. Bogni
    A. Coliva
    S. Lo Vullo
    E. Bombardieri
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 223 - 230
  • [7] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S373 - S373
  • [8] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S179 - S179
  • [9] Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy
    Seregni, E.
    Maccauro, M.
    Chiesa, C.
    Mariani, L.
    Pascali, C.
    Mazzaferro, V.
    De Braud, F.
    Buzzoni, R.
    Milione, M.
    Lorenzoni, A.
    Bogni, A.
    Coliva, A.
    Lo Vullo, S.
    Bombardieri, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (02) : 223 - 230
  • [10] Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S178 - S179
12345